A major obstacle in Tuberculosis (TB) control is the long duration of treatment. Therefore, treatment shortening is one of the highest priorities for TB control programs worldwide. Fluoroquinolones (FQ) have been found to be highly active against Mycobacterium Tuberculosis and recommended as second line agents for TB treatment. Recent evidences have shown that the newer generation FQ add to the effects of existing anti-TB drugs and perhaps allow TB treatment to be shortened. However, no review has been published on the role of FQ in shortening TB treatment duration. This book, therefore, is...